BSE SENSEX
48,564.27-470.40(-0.96%)Nifty 50
14,281.30-152.40(-1.06%)Dow
30,814.30-177.24(-0.57%)
Cipla Limited (CIPLA.NS)
- Reuters
Indian demand for COVID-19 drug remdesivir rising sharply - Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness. Remdesivir was developed by U.S. drugmaker Gilead Sciences Inc <GILD.O>, which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.
- Reuters
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.
- Reuters
India's shortage of remdesivir is easing, says producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd. Remdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations. Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Cipla's Global Chief Financial Officer, Kedar Upadhye, told Reuters.
